with H Bester, Economic Journal, 2018, DOI
The most recent unpublished version is here: Credence_EJ_forthcoming (November 2016).
Click here for longer summary.
We study contracting between a consumer and an expert. Continue reading
industrial & health economics
The Enforcement of Mandatory Disclosure Rules
with P González and N Porteiro, Journal of Public Economics, 2018, DOI
The most recent unpublished version is here: DahmEtAlEnforcementDisclosure (August 2018).
Click here for longer summary.
This paper examines the incentives of firms to invest in information about product risk and to disclose its findings. Continue reading
Dual Sourcing with Price Discovery
with J Alcalde, Games and Economic Behavior, 2019, DOI
The most recent unpublished version is here: DualSourcingR3 (February 2019).
Click here for longer summary.
Reverse auctions are considered a fast and inexpensive price discovery tool to award procurement contracts and it is often desirable to award contracts to more than one supplier. Continue reading
Competition for Procurement Shares
with J Alcalde, Games and Economic Behavior, 2013, DOI
We propose a new procurement procedure that allocates shares of the total amount to be procured depending on the bids of suppliers. Continue reading
On the Complete Information First-Price Auction and its Intuitive Solution
with J Alcalde, International Game Theory Review, 2011, DOI
Despite the popularity of auction theoretical thinking, it appears that no one has presented an elementary equilibrium analysis of the complete information first-price sealed-bid auction mechanism Continue reading
Implementing Registries and Results Databases of Clinical Trials: Is There a Side Effect?
with P González and N Porteiro, Expert Review of Pharmacoeconomics & Outcomes Research, 2010, DOI
Many parts of the world are currently witnessing a controversial discussion concerning the appropriate design of the environment for clinical trials. Continue reading
Trials, Tricks and Transparency: How Disclosure Rules Affect Clinical Knowledge
with P González and N Porteiro, Journal of Health Economics, 2009, DOI
Scandals of selective reporting of clinical trial results by pharmaceutical firms have underlined the need for more transparency in clinical trials. We provide a theoretical framework Continue reading
Matthias Dahm's web site 